Table 2 Concurrent result of CSF cytology, CSF ctDNA and neuroimaging findings in patients with MC
No. | CSF immunocytochemistry | Neuroimaging findings | Concurrent result of CSF cytology | Concentration of CSF ctDNA (ng/ul) | CSF ctDNA gene mutations (mutation frequency) | Parenchymal brain metastasis |
|---|---|---|---|---|---|---|
N01 | CK7(+), Ki-67(+), ER(−), PR(−) | Leptomeningeal enhancement | + | 5.36 | TP53 R196* (68.55%) VHL R200W (5.19%) | _ |
N02 | Ki-67(+), CK7(+), ER(−), FR(−) | Leptomeningeal enhancement | + | 0.512 | PTEN K13Q (0.455%) NOTCH1 (38.86%) | _ |
N03 | Ki-67(+), CEA(−), CK20(−), CK7(−), CK20(−) | Leptomeningeal enhancement | + | 0.204 | PTEN K13Q (0.311%) | + |
N04 | Ki-67(+), CEA(+) | Leptomeningeal enhancement | + | 2.08 | TP53 L194R (45.69%) | _ |
N05 | Not available | Leptomeningeal enhancement | _ | 1.17 | TP53R248Q (1.464%) | _ |
N06 | Not available | Leptomeningeal enhancement | _ | 1.36 | PTEN R14G (0.204%) | _ |
N07 | Not available | Leptomeningeal enhancement | _ | 0.29 | TP53 P301Q (0.761%) | _ |
N08 | CK7 (+) | Leptomeningeal enhancement | + | 6.82 | TP53 C242G (72.914%) | _ |
N09 | NapsinA (+), CK7(+) | Negative | + | 0.144 | TP53 I195F (89.921%) | _ |
N10 | Not available | Negative | + | 0.238 | TP53 F113 V (55.412%) | _ |
N11 | NapsinA (+), TTF1(+), CK7(+) | Negative | + | 5.36 | TP53 R337C (53.924%) | _ |
N12 | CK7(+), NapsinA(+), Ki-67(−), TTF1(−), CDX2(−), CD20(−) | Leptomeningeal enhancement | + | 1.74 | EGFR L858R (82.178%) | + |
N13 | TTF1(+), NapsinA (+) | Negative | + | 3.46 | EGFR L858R (29.903%) | _ |
N14 | Not available | Leptomeningeal enhancement | _ | 3.52 | EGFR L858R (33.003%) | _ |
N15 | Not available | Negative | + | 3.08 | EGFR L858R (14.159%) | _ |
N16 | Not available | Negative | _ | 25.6 | EGFR L858R (0.229%) | _ |
N17 | Not available | Leptomeningeal enhancement | + | 1.65 | TP53 P301Q (0.482%) | _ |
N18 | Not available | Negative | + | 2.26 | EGFR E746_A750del (38.178%) | _ |
N19 | Not available | Leptomeningeal enhancement | _ | 30.6 | EGFR T790 M (22.61%) | _ |
N20 | Not available | Leptomeningeal enhancement | + | 2.58 | TP53 G245S (0.497%) | _ |
N21 | Not available | Negative | + | 26.6 | EGFR L858R (78.401%) | _ |
N22 | NapsinA(+), TTF1(−), Ki-67(−), CEA(+) | Negative | + | 1.42 | EGFR L858R (12.359%) | _ |
N23 | Not available | Negative | + | 2.76 | EGFR L858R (24.468%) | _ |
N24 | Not available | Negative | + | 3.58 | EGFR L858R (5.535%) | _ |
N25 | NapsinA(+) | Leptomeningeal enhancement | + | 2.92 | PTEN C136Y (1.431%) | _ |
N26 | Not available | Leptomeningeal enhancement | + | 7.54 | EGFR T790 M (6.286%) | _ |
N27 | CK7(−), Ki-67(−), TTF1(−), NapsinA(−), CK20(−), CDX20(−), CDX2(−), CEA(−), FAP(−) | Leptomeningeal enhancement | + | 1.23 | EGFR L858R (79.739%) | + |
N28 | Not available | Leptomeningeal enhancement | – | 4.1 | EGFR L858R (1.606%) | + |
N29 | Not available | Negative | + | 3.36 | PTEN K13Q (0.387%) | _ |
N30 | Not available | Negative | + | 4.16 | EGFR L858R (24.22%) | _ |
N31 | CK7(+), NapsinA(+), Ki-67(−), PR(−), TTF1(−) | Leptomeningeal enhancement | + | 4.04 | EGFR T790 M (5.233%) | _ |
N32 | Ki-67(−), CEA(+), CK7(+), TTF1(+), CDX2(−), CK20(−), NapsinA(+), ER(−), PR(−) | Leptomeningeal enhancement | + | 3.8 | EGFR L858R (3.74%) | _ |
N33 | Not available | Leptomeningeal enhancement | _ | 1.51 | PTEN K13Q (0.464%) | + |
N34 | Not available | Leptomeningeal enhancement | _ | 1.09 | TP 53 P250L (84.24%) | _ |
N35 | Not available | Leptomeningeal enhancement | _ | 1.42 | FLT3 Y842C (0.404%) | _ |